[go: up one dir, main page]

ES2113322B1 - RECOMBINANT MIXOMATOUS VIRUSES. - Google Patents

RECOMBINANT MIXOMATOUS VIRUSES.

Info

Publication number
ES2113322B1
ES2113322B1 ES09601551A ES9601551A ES2113322B1 ES 2113322 B1 ES2113322 B1 ES 2113322B1 ES 09601551 A ES09601551 A ES 09601551A ES 9601551 A ES9601551 A ES 9601551A ES 2113322 B1 ES2113322 B1 ES 2113322B1
Authority
ES
Spain
Prior art keywords
mixomatous
viruses
recombinant
vaccine
leporids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES09601551A
Other languages
Spanish (es)
Other versions
ES2113322A1 (en
Inventor
Stephane Bertagnoli
Jacqueline Gelfi
Corine Boucrautbaralon
Frederque Petit
Alain Milon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Recherche Agronomique INRA
Ecole Nationale Veterinaire de Toulouse ENVT
Original Assignee
Institut National de la Recherche Agronomique INRA
Ecole Nationale Veterinaire de Toulouse ENVT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Recherche Agronomique INRA, Ecole Nationale Veterinaire de Toulouse ENVT filed Critical Institut National de la Recherche Agronomique INRA
Publication of ES2113322A1 publication Critical patent/ES2113322A1/en
Application granted granted Critical
Publication of ES2113322B1 publication Critical patent/ES2113322B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

VIRUS MIXOMATOSO RECOMBINANTE. VIRUS MIXOMATOSO RECOMBINANTE ATENUADO, QUE COMPRENDE POR LO MENOS UNA SECUENCIA NUCLEOTIDICA QUE CODIFICA PARA, Y QUE EXPRESA, UN POLIPEPTIDO ANTIGENO, BAJO LA DEPENDENCIA DE UN PROMOTOR, ESTANDO DICHA SECUENCIA Y DICHO PROMOTOR INSERTADOS EN UNO DE LOS GENES NO ESENCIAL PARA LA REPLICACION DE DICHO VIRUS. UTILIZACION DE DICHO VIRUS PARA LA FABRICACION DE UNA VACUNA DESTINADA A VACUNAR A LOS LEPORIDOS DE FORMA EFICAZ Y AL MISMO TIEMPO CONTRA LA MIXOMATOSIS Y CONTRA OTRA PATOLOGIA, ESPECIALMENTE LA RVHD. TAMBIEN SE REFIERE A UNA VACUNA PARA LEPORIDOS QUE COMPRENDE COMO VECTOR DICHO VIRUS MIXOMATOSO RECOMBINANTE ATENUADO.RECOMBINANT MIXOMATOUS VIRUSES. ATTENUATED RECOMBINANT MIXOMATOUS VIRUS, WHICH INCLUDES AT LEAST ONE NUCLEOTIDIC SEQUENCE THAT CODES FOR, AND THAT EXPRESSES, AN ANTIGEN POLYPEPTIDE, UNDER THE DEPENDENCY OF A PROMOTER REPORTED BY A GENERATOR OF THESE INSERTED SAID VIRUSES. USE OF SUCH VIRUSES TO MANUFACTURE A VACCINE INTENDED TO VACCINE LEPORIDS EFFECTIVELY AND AT THE SAME TIME AGAINST MYXOMATOSIS AND AGAINST OTHER PATHOLOGY, ESPECIALLY RVHD. IT ALSO CONCERNS A VACCINE FOR LEPORIDS THAT IS UNDERSTANDED AS A VECTOR SUCH ATTENUATED RECOMBINANT MIXOMATOUS VIRUS.

ES09601551A 1995-07-05 1996-07-05 RECOMBINANT MIXOMATOUS VIRUSES. Expired - Fee Related ES2113322B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9508128A FR2736358B1 (en) 1995-07-05 1995-07-05 RECOMBINANT MYXOMATOUS VIRUS

Publications (2)

Publication Number Publication Date
ES2113322A1 ES2113322A1 (en) 1998-04-16
ES2113322B1 true ES2113322B1 (en) 1998-12-01

Family

ID=9480712

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09601551A Expired - Fee Related ES2113322B1 (en) 1995-07-05 1996-07-05 RECOMBINANT MIXOMATOUS VIRUSES.

Country Status (4)

Country Link
DE (1) DE19627193B4 (en)
ES (1) ES2113322B1 (en)
FR (2) FR2736358B1 (en)
IT (1) IT1286307B1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2153284B1 (en) * 1998-06-10 2001-09-01 Fundacion Para El Estudio Y De NEW RECOMBINANT VIRUS OF ATTENATED MIXOMA AND ITS USE IN THE PREPARATION OF MIXED VACCINES AGAINST MIXOMATOSIS AND HEMORRAGICAL DISEASE OF THE RABBITS.
ES2258628T3 (en) * 2001-03-08 2006-09-01 Akzo Nobel N.V. LEPORIPOX-BASED VECTOR VACCINES.
FR2946536B1 (en) 2009-06-11 2011-07-29 Agronomique Inst Nat Rech USE OF AN ATXURATED STRAIN OF MYXOMA VIRUS AS AN ONCOLYTIC
WO2017037523A1 (en) 2015-06-19 2017-03-09 Sillajen, Inc. Compositions and methods for viral embolization

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869312A (en) * 1992-01-13 1999-02-09 Syntro Corporation Recombinant swinepox virus

Also Published As

Publication number Publication date
DE19627193B4 (en) 2007-08-30
FR2736358B1 (en) 1997-09-26
FR11C0050I2 (en) 2012-06-22
FR11C0050I1 (en) 2011-12-16
FR2736358A1 (en) 1997-01-10
ES2113322A1 (en) 1998-04-16
ITTO960578A1 (en) 1998-01-05
IT1286307B1 (en) 1998-07-08
DE19627193A1 (en) 1997-03-20
ITTO960578A0 (en) 1996-07-05

Similar Documents

Publication Publication Date Title
AR020080A1 (en) A VACCINE FOR THERAPEUTIC OR PROFILACTIC IMMUNIZATION AGAINST VENEZUELAN EQUINE ENCEPHALITIS VIRUS, AND, A PHARMACEUTICAL COMPOSITION
ES2664505T3 (en) Sequences of serotype 9 of adeno-associated virus (AAV), vectors containing them, and uses thereof
PT1294893E (en) MODIFICATION OF HEPATITIS B NUCLEAR ANTIGEN
ES2191663T3 (en) RECOMBINING VIRUS OF THE PORCINE VIRUELA.
ES2061996T3 (en) NON-ESSENTIAL REGIONS OF AVIPOXVIRUSES.
BR9912410A (en) Vaccine for immunizing birds, and processes for immunizing a bird and for preparing a vaccine to immunize a bird
BR9605153B1 (en) combination vaccine and vaccination kit.
TR199900267T2 (en) GnRH-L�kotoksin kimeralar�.
ES2124532T3 (en) VECTOR-GUEST SYSTEM USABLE IN GENE THERAPY.
ES2163394T3 (en) SERREREACTIVE REGIONS SITUATED IN THE HPV16 E1 AND E2 PROTEINS.
ES2143507T3 (en) VACCINES AGAINST AUJESZKY DISEASE AND OTHER ANIMAL DISEASES CONTAINING MUTANTS OF PSEUDORRABIA VIRUSES.
AR248045A1 (en) Recombinant avipox virus
AR025503A1 (en) VACCINE COMPOSITIONS FOR HEPATITIS AND HPV
ES2113322B1 (en) RECOMBINANT MIXOMATOUS VIRUSES.
DE69112634D1 (en) IMMUNOGENOUS COMPLEXES, IN PARTICULAR ISCOMS.
Kraus et al. Vaccination directed against the human endogenous retrovirus-K (HERV-K) gag protein slows HERV-K gag expressing cell growth in a murine model system
DK366483A (en) GENES, DNA TRANSFER VECTOR OR SUBSTANCE THAT CODES FOR HUMAN PREPRORELAXIN OR A SUBSTANCE THEREFORE
ES2134197T3 (en) VACCINES AGAINST HERPES SIMPLEX VP16 VIRUSES.
KR940003566A (en) Recombinant Adenovirus Vaccine
AR019250A1 (en) DAMAGED FORMS OF BOVINE VIRAL DIARREA VIRUS, NUCLEIC ACID MOLECULA, VECTOR, USE, METHOD TO MODIFY THE WILD TYPE VIRAL GENOME, MODIFIED GENOME, VACCINE, METHOD TO DENIM A WILD VIRUS VIRUS
ES8403319A1 (en) Infectious bronchitis vaccines.
Lokhandwala et al. Priming cross-protective bovine viral diarrhea virus-specific immunity using live-vectored mosaic antigens
ES2118242T3 (en) VACCINES ANTI VIRUSES OF FELINE IMMUNODEFICIENCY (IVF).
MXPA94008605A (en) Viral vector with bovine viral diarrhea virus (bvdv) antigens.
ES2070846T3 (en) RNA-VIRUS WITHOUT REVERSION.

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19980416

Kind code of ref document: A1

Effective date: 19980416

FD2A Announcement of lapse in spain

Effective date: 20161026